JP2002517467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002517467A5 JP2002517467A5 JP2000553127A JP2000553127A JP2002517467A5 JP 2002517467 A5 JP2002517467 A5 JP 2002517467A5 JP 2000553127 A JP2000553127 A JP 2000553127A JP 2000553127 A JP2000553127 A JP 2000553127A JP 2002517467 A5 JP2002517467 A5 JP 2002517467A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- secretin
- disorder
- crystalline
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 102100037505 Secretin Human genes 0.000 description 8
- 108010086019 Secretin Proteins 0.000 description 8
- 229960002101 secretin Drugs 0.000 description 8
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8857598P | 1998-06-09 | 1998-06-09 | |
| US60/088,575 | 1998-06-09 | ||
| US09/229,208 US6197746B1 (en) | 1998-05-19 | 1999-01-13 | Method of using secretin for treating autism |
| US09/229,208 | 1999-01-13 | ||
| PCT/US1999/013061 WO1999064059A2 (en) | 1998-06-09 | 1999-06-09 | Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002517467A JP2002517467A (ja) | 2002-06-18 |
| JP2002517467A5 true JP2002517467A5 (https=) | 2007-04-05 |
Family
ID=26778819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553127A Withdrawn JP2002517467A (ja) | 1998-06-09 | 1999-06-09 | 自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6197746B1 (https=) |
| EP (1) | EP1085901B1 (https=) |
| JP (1) | JP2002517467A (https=) |
| AT (1) | ATE322283T1 (https=) |
| AU (1) | AU772911B2 (https=) |
| CA (1) | CA2333657A1 (https=) |
| DE (1) | DE69930739D1 (https=) |
| WO (1) | WO1999064059A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2290556A1 (en) * | 1997-05-19 | 1998-11-26 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| US6020314A (en) * | 1998-08-11 | 2000-02-01 | Milkhaus Laboratory, Inc. | Methods for treatment of neurological disorders |
| WO2001037801A1 (en) * | 1999-11-22 | 2001-05-31 | Rogoff Joseph A | Secretin and secretin pharmaceuticals for treating attention deficit disorder |
| US6534063B1 (en) | 1999-12-17 | 2003-03-18 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US6632429B1 (en) * | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| GB0008326D0 (en) * | 2000-04-06 | 2000-05-24 | Shs International Ltd | Diagnosis and treatment of autism and related disorders |
| GB0016441D0 (en) | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
| AU2001284865A1 (en) * | 2000-08-14 | 2002-02-25 | Joan M. Fallon | Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
| US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| AU8676301A (en) * | 2000-08-25 | 2002-03-04 | Res Corp Technologies Inc | New uses for amino acid anticonvulsants |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| GB0118383D0 (en) * | 2001-07-27 | 2001-09-19 | Pharmagene Lab Ltd | Therapeutic methods |
| US6585996B1 (en) | 2002-03-13 | 2003-07-01 | Westlake Laboratories, Inc. | Lipid-soluble thiamine derivatives in the treatment of autism |
| US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
| US20050002922A1 (en) * | 2003-03-12 | 2005-01-06 | Richard Boismenu | Use of secretin and secretin analogs to treat affective disorders |
| WO2004080476A1 (en) * | 2003-03-12 | 2004-09-23 | University Of North Carolina At Chapel Hill | Use of secretin in the treatment of schizophrenia |
| WO2004100899A2 (en) * | 2003-05-13 | 2004-11-25 | The Mclean Hospital Corporation | Use of secretin in treatments of disorders associated with the amygdala |
| US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
| US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| GB0504096D0 (en) * | 2005-02-28 | 2005-04-06 | Tipogen As | Method |
| US20070034214A1 (en) * | 2005-08-12 | 2007-02-15 | Dochniak Michael J | Method to affect the development of autism spectrum disorders |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) * | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US9320780B2 (en) * | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| EP2318035B1 (en) * | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| CA2747611C (en) | 2009-01-06 | 2019-09-17 | Curemark Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| WO2010080835A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| JP2013507394A (ja) * | 2009-10-09 | 2013-03-04 | プロセラ インコーポレイテッド | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| WO2011123695A1 (en) * | 2010-03-31 | 2011-10-06 | Abela Pharmaceuticals, Inc. | Dimethy sulfoxxide (dmso) formulations for treating autism |
| US8962042B2 (en) | 2010-09-28 | 2015-02-24 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| US9931365B2 (en) | 2010-09-28 | 2018-04-03 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| JP5976100B2 (ja) | 2011-04-21 | 2016-08-23 | キュアマーク リミテッド ライアビリティ カンパニー | 神経精神障害の処置のための化合物 |
| US9442092B2 (en) | 2011-06-20 | 2016-09-13 | Kerry Lane | Methods for treatment of autism |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
| US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| CN109908120B (zh) * | 2019-04-22 | 2022-04-19 | 井冈山大学 | 一种狭顶鳞毛蕨有效成分、提取方法及其应用 |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833722A (en) | 1971-03-16 | 1974-09-03 | D Graybill | Method for controlling allergies |
| JPS5029005B2 (https=) * | 1972-05-08 | 1975-09-19 | ||
| US3987014A (en) | 1974-01-10 | 1976-10-19 | Becton, Dickinson And Company | Secretin intermediates and derivatives |
| DE2615229C2 (de) | 1976-04-08 | 1984-05-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung und Reinigung von Sekretin |
| US4086220A (en) | 1976-08-09 | 1978-04-25 | G. D. Searle & Co. | Fragments of secretin |
| DE3066483D1 (en) | 1979-06-13 | 1984-03-15 | Hoechst Ag | Pharmaceutical compositions based on secretin with enhanced and protracted activity, process for their preparation and dihydroxybenzoyl-l-tyrosine |
| NZ196349A (en) | 1980-03-07 | 1984-08-24 | Interx Research Corp | Enhancement of absorption rate of orally administered polar bioactive agents |
| JPS58140024A (ja) | 1982-02-15 | 1983-08-19 | Eisai Co Ltd | セクレチンの精製方法 |
| DE3328793A1 (de) | 1983-08-10 | 1985-02-28 | Hoechst Ag, 6230 Frankfurt | Herstellung von sekretin |
| SE454513B (sv) | 1985-03-11 | 1988-05-09 | Kabigen Ab | Humant sekretin samt kompositioner innehallande detta |
| JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| US5008251A (en) | 1986-03-27 | 1991-04-16 | The Regents Of The University Of California | Method of treating autism |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5094837A (en) | 1990-01-22 | 1992-03-10 | Wayne State University | Method for use of magnetic resonance imaging to image pancreas using secretin |
| US5225407A (en) | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| US5380872A (en) * | 1992-07-14 | 1995-01-10 | Glaxo Inc. | Modulators of cholecystokinin |
| EP0681491B1 (en) | 1993-01-29 | 2000-12-13 | Aradigm Corporation | Intrapulmonary delivery of hormones |
| US5527825A (en) | 1994-04-06 | 1996-06-18 | University Of Arkansas | Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase |
| US5560910A (en) * | 1994-08-26 | 1996-10-01 | Crandall; Wilson T. | Topical anti-inflammatory composition and method |
| GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| US5686311A (en) | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
| CA2290556A1 (en) * | 1997-05-19 | 1998-11-26 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| AU745385B2 (en) | 1997-09-11 | 2002-03-21 | Regents Of The University Of California, The | Plus end-directed microtubule motor required for chromosome congression |
-
1999
- 1999-01-13 US US09/229,208 patent/US6197746B1/en not_active Expired - Fee Related
- 1999-06-09 AT AT99927416T patent/ATE322283T1/de not_active IP Right Cessation
- 1999-06-09 DE DE69930739T patent/DE69930739D1/de not_active Expired - Lifetime
- 1999-06-09 JP JP2000553127A patent/JP2002517467A/ja not_active Withdrawn
- 1999-06-09 CA CA002333657A patent/CA2333657A1/en not_active Abandoned
- 1999-06-09 WO PCT/US1999/013061 patent/WO1999064059A2/en not_active Ceased
- 1999-06-09 AU AU44322/99A patent/AU772911B2/en not_active Ceased
- 1999-06-09 EP EP99927416A patent/EP1085901B1/en not_active Expired - Lifetime
-
2001
- 2001-03-05 US US09/800,431 patent/US6790825B2/en not_active Expired - Fee Related
-
2003
- 2003-08-08 US US10/637,250 patent/US20050249714A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002517467A5 (https=) | ||
| MA27316A1 (fr) | Derives d'indoline-phenylsulfonamide | |
| Brown et al. | Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors | |
| HUP0204085A3 (en) | New oxabispidine compounds useful in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them | |
| EP3320902B1 (en) | Methods for treating diseases using isoindoline compounds | |
| EP0384285A3 (en) | Piperidine compounds and their preparation and use | |
| AU2002359164A8 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| CA2284732A1 (en) | Analogs of cocaine | |
| CA2191101A1 (en) | Materials and methods for treatment of plaquing diseases | |
| CA2031714A1 (en) | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them | |
| YU69003A (sh) | Aril i heteroaril urea chk1 inhibitori kao jedinjenja koja povećavaju osetljivost na radioterapiju i hemoterapiju | |
| WO2001085145A3 (en) | A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | |
| NO20014816D0 (no) | Derivater av venlafaxin og fremgangsmåter for fremstilling og andvendelse av samme | |
| IL164225A (en) | Derivatives of benzensulfonyl - methyl - amino-pyrimidin - 4 - ylamino, pharmaceutical compositions comprising them and their use for the manufacture of medicaments for treating diseases mediated by alpha 4 integrin and a process for their preparation | |
| CA2498291A1 (en) | Diazabicyclic compounds useful in the treatment of cns and other disorders | |
| CA2436540A1 (en) | Pharmaceutical compositions based on anticholinergics and corticosteroids | |
| AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| IL132599A0 (en) | Substituted 3,3-diamino-2-propenenitriles their preparation and use | |
| WO2002060435A8 (fr) | Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer | |
| HUP0401325A3 (en) | Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds | |
| ATE375144T1 (de) | Echogene polymermikrokapseln und nanokapseln und verfahren zu ihrer herstellung und verwendung | |
| EP1586644A3 (en) | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour development and for wound healing | |
| WO1999058490A3 (en) | Novel aryl-hydro naphthalenal kanamines | |
| WO2000003978A3 (de) | 2,5-substituierte benzolsulfonylharnstoffe und -thioharnstoffe, v,rfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate | |
| ES2009689A6 (es) | Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima. |